{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-044230","form_type":"8-K","ticker":null,"cik":"0001463361","company_name":"Unity Biotechnology, Inc.","filed_at":"2024-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.503978+00:00","generated_at":"2026-06-03T22:52:29.234641+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Unity Biotech reports FY 2023 net loss $39.9M; Phase 2b ASPIRE DME study upsized to 50 patients","bullets":["Cash, equivalents and marketable securities $43.2M as of Dec 31, 2023; runway into Q3 2025.","Net loss FY 2023 $39.9M (down from $44.5M in 2022); Q4 net loss $4.3M (down from $7.4M).","R&D expenses decreased $16.8M to $20.1M in FY 2023 due to completion of BEHOLD/ENVISION studies and headcount reduction.","Phase 2b ASPIRE study in DME (UBX1325 vs aflibercept) upsized to 50 patients; 16-week data expected Q4 2024, 24-week data Q1 2025.","Published research in Nature Medicine in Jan 2024 on targeting cellular senescence in DME."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-044230","json":"https://secwatch.observer/filing/0000950170-24-044230.json","markdown":"https://secwatch.observer/filing/0000950170-24-044230.md","text":"https://secwatch.observer/filing/0000950170-24-044230.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1463361/000095017024044230/0000950170-24-044230-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1463361/000095017024044230/ubx-20240415.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:52:29.234641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2754f67568572b37b1c8c4055704b455aaedd931","claim":"Unity Biotechnology, Inc. reported fourth quarter and full year ended December 31, 2023 results: net income Net loss for the twelve months ended December 31, 2023 was $39.9 million.","evidence_excerpt":"On April 15, 2024, Unity Biotechnology, Inc. (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1463361/000095017024044230/0000950170-24-044230-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Net income","value":"Net loss for the twelve months ended December 31, 2023 was $39.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}